Aktive Positionen von David Yeomans
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
SiteOne Therapeutics, Inc.
 SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | Gründer | 01.01.2010 | - |
Trigemina, Inc.
 Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2006 | - |
| Gründer | 01.01.2006 | - |
Karriereverlauf von David Yeomans
Statistik
International
| Vereinigte Staaten | 3 |
Operativ
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | Health Technology |
Trigemina, Inc.
Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | Health Technology |
- Börse
- Insiders
- David Yeomans
- Erfahrung